Yes. Where possible, they want recurring revenue, at least for...

Yes. Where possible, they want recurring revenue, at least for the Pulse. "Leasing" for doctors was the word I remember, but maybe someone misspoke and meant SaaS or something. Of course, there will be OTC upfront sales, if FDA clears it, but then the product will have limited functionality, which consumers can increase to full functionality by paying a small monthly fee. Imagine global recurring revenues for multiple products used by big pharma, hospitals, medical practices, and consumers. You can see why they are targeting a multi-billion dollar market cap.